Abstract #4723

Early MR-detectable biomarkers of mutant IDH inhibition in patient-derived low-grade gliomas in vivo

Marina Radoul¹, Chloé Najac¹, Donghyun Hong¹, Anne Marie Gillespie¹, Pavithra Viswanath¹, Russell O. Pieper^2,3, Joseph F. Costello², and Sabrina M. Ronen^1,3

¹Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States, ²Neurological Surgery, University of California San Francisco, San Francisco, CA, United States, ³Brain Tumor Research Center, University of California San Francisco, San Francisco, CA, United States

Low-grade glioma (LLG) patients have a relatively long-term survival of ~13 years but these tumors always recur. Since IDH mutations are present in >80% of LGGs, inhibition of mutant IDH activity is being tested as a new therapeutic approach. Here, we investigated response to mutant IDH inhibition by AG-881 in orthotopic LGG mouse models. Using in vivo ¹H MRS we detected, in addition to a decrease in 2-HG, an early increase in both glutamate and glutamine/glutamate that were associated with subsequent tumor shrinkage. This identifies potential early metabolic biomarkers of LGG response to mutant IDH inhibition.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.